Inventor · disambiguated record
Tom Tong Lee
Also filed as: LEE TOM · LEE TOM T · LEE TOM TONG
13 granted patents·20 pending applications·80 citations·filing 2012–2025
89Inventor score
Top patents by PatentIndex Score
33 records- 0197US11365394B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Jun 21, 2022·14 cites·20 claims
- 0296US10927346B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·17 cites·22 claims
- 0396US10287606B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2017·Granted May 14, 2019·28 cites·24 claims
- 0495US11072781B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·18 cites·18 claims
- 0587US11352607B2Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·2 cites·28 claims
- 0676US2025032547A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0775US12203098B2Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Granted Jan 21, 2025·0 cites·30 claims
- 0875US12173274B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2021·Granted Dec 24, 2024·0 cites·22 claims
- 0973US12398373B2Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2018·Granted Aug 26, 2025·0 cites·26 claims
- 1073US12122846B2Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·16 claims
- 1173US2025145966A1Enhanced immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1272US2021324340A1Genomic engineering of pluripotent cellsFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1372US2025228943A1Cells having solid tumor targeting backbone and use thereofFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1470US2025222029A1Chimeric antigen receptor for tumor targetingFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1569US2025000904A1Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumorsFATE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1663US2025388646A1Enhancing effector cell durability and efficacy in adoptive cell therapiesFATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1761US2021163622A1Immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1860US12435123B2Immunotherapies using enhanced iPSC derived effector cellsFATE THERAPEUTICS INC·Filed 2019·Granted Oct 7, 2025·0 cites·28 claims
- 1959US2022275333A1Immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2058US9403885B2Wnt compositions and therapeutic uses of such compositionsLEE TOM TONG·Filed 2012·Granted Aug 2, 2016·1 cites·18 claims
- 2158US2023381235A1Multiplexed engineered ipscs and immune effector cells targeting solid tumorsFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2257US10634587B2Systems, methods and components for isolating cells from a fluid sampleUNIV CALIFORNIA·Filed 2018·Granted Apr 28, 2020·0 cites·29 claims
- 2354US2023405121A1Engineered ipsc and immune effector cells for heterogenous tumor controlFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2453US2024033355A1ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLSFATE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2552US2024115602A1Enhanced chimeric antigen receptor for immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2652US2024226293A9Enhanced chimeric antigen receptor for immune effector cell engineering and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2752US2022378831A1Multi-targeting effector cells and use thereofFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2849US2022184142A1CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLSFATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2948US2015285717A1Systems, methods and components for isolating cells from a fluid sampleUNIV CALIFORNIA·Filed 2013·Application pending·0 cites
- 3048US2021015859A1IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLSFATE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3148US2021024959A1Engineered immune effector cells and use thereofFATE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3238US9873722B2Wnt compositions and therapeutic uses of such compositionsLEE TOM TONG·Filed 2012·Granted Jan 23, 2018·0 cites·12 claims
- 3334US2014171625A1Cardiotrophin related molecules for enhanced therapeuticsLEE TOM TONG·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tom Tong Lee files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →